New donors, new recipients--who gets what in 2003?

Transfus Clin Biol

Blood Transfusion at the National Blood Service, North London and Hammersmith Hospitals NHS Trust, London, UK.

Published: February 2004

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tracli.2003.11.006DOI Listing

Publication Analysis

Top Keywords

donors recipients--who
4
recipients--who 2003?
4
donors
1
2003?
1

Similar Publications

Purpose: Highly sensitized patients (HSPs) with kidney failure have limited access to kidney transplantation and poorer post-transplant outcomes. Prioritizing HSPs in kidney allocation systems and expanding the pool of deceased donors available to them has helped to reduce their wait times for transplant and enhanced post-transplant outcomes. The Canadian HSP Program was established by Canadian Blood Services in collaboration with provincial organ donation and transplantation programs throughout the country to increase transplant opportunities for transplant candidates needing very specific matches from deceased kidney donors.

View Article and Find Full Text PDF

Background: Predicted heart mass ratio (PHMr) has become the standard donor-recipient size matching method in heart transplantation. While utilization of small PHMr hearts is associated with increased one-year mortality, the underlying mechanisms and time horizon of mortality remain uncertain.

Methods: A single institution analysis of isolated heart transplant recipients (01/2019-7/2022) was performed (N=334).

View Article and Find Full Text PDF

Background: The impact of kidney transplantation (KT) on left ventricular (LV) remodeling remains poorly understood. This study aimed to evaluate the effect of KT on LV reverse remodeling, utilizing echocardiographic LV geometric patterns as a key assessment tool.

Methods: In 100 recipients who underwent living KT between 2012 and 2022, we evaluated changes in the distribution of LV geometric patterns (normal geometry, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy) between baseline and 1 year post-transplantation.

View Article and Find Full Text PDF

Physician-Directed Mycophenolate Mofetil Dose Reduction After Kidney Transplantation: A Multicenter Real Word Experience.

Transplant Proc

December 2024

The William J. von Liebig Center for Transplantation and Clinical Regeneration, Rochester, Minnesota; Department of Surgery and Immunology, Mayo Clinic, Rochester, Minnesota.

Background: Mycophenolate mofetil (MMF) dose is commonly reduced after kidney transplantation (KT). This study examined MMF dosing in the first 5 years after KT to determine if a lower MMF dose impacted outcomes.

Methods: We retrospectively studied 432 recipients who underwent KT between February 2012 and February 2015 in 3 centers.

View Article and Find Full Text PDF

HLA-compatibility remains an important triage test for deceased donor kidney allocation. Low-intermediate resolution donor HLA-typing is typically available at allocation, but its accuracy in assigning pre-transplant donor-specific anti-HLA antibody (DSA) and HLA mismatches compared to 2-field high-resolution typing is poorly characterised. Consecutive deceased donor/recipient pairs from a single centre between 2016 and 2020 were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!